Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIT | P10721 | 3/20 | 0.64 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.62 |
| ▸ | BRAF | P15056 | 2/20 | 0.62 |
| ▸ | HTT | P42858 | 3/20 | 0.61 |
| ▸ | ATM | Q13315 | 2/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.60 |
| ▸ | MAP4K2 | Q12851 | 1/20 | 0.60 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.60 |
| ▸ | CLK1 | P49759 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | STK10 | O94804 | 1/20 | 0.58 |
| ▸ | ABL1 | P00519 | 1/20 | 0.58 |
| ▸ | RET | P07949 | 1/20 | 0.58 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.58 |
| ▸ | FLT1 | P17948 | 1/20 | 0.58 |
| ▸ | CDK11B | P21127 | 1/20 | 0.58 |
| ▸ | CDK2 | P24941 | 1/20 | 0.58 |
| ▸ | FLT4 | P35916 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL589012 | 0.92 | KIT (0.75) | KITBRAFABL1RET | |
| SCHEMBL1420613 | 0.89 | CHRM4 (0.67) | KITEPHA2BRAFHTTATM | |
| SCHEMBL20568827 | 0.89 | EPHA2 (0.63) | KITEPHA2BRAFHTTATM | |
| SCHEMBL1420251 | 0.88 | EPHA2 (0.62) | KITEPHA2BRAFHTTATM | |
| SCHEMBL16236572 | 0.86 | KIT (0.63) | KITEPHA2BRAFHTTATM | |
| SCHEMBL16236899 | 0.85 | KIT (0.86) | KITBRAFHTTATMKMT2A | |
| SCHEMBL15688171 | 0.85 | MKNK2 (0.64) | KITHTTATMKMT2AABL1 | |
| SCHEMBL28054362 | 0.84 | HTT (0.65) | KITBRAFHTTATMKMT2A | |
| SCHEMBL17182047 | 0.83 | ABL1 (0.63) | KITEPHA2BRAFHTTATM | |
| SCHEMBL30309801 | 0.82 | KIT (0.69) | KITBRAFHTTATMKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2917214-B1 | SUBSTITUTED PYRIMIDINYL AND PYRIDINYL-PYRROLOPYRIDINONES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2019-08-28 | — | — | EP | disclosed |
| US-9682083-B2 | Pyrrolo[2,3-D]pyrimidine derivatives, process for their preparation and their use as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2017-06-20 | — | — | US | disclosed |
| US-9604980-B2 | Substituted pyrimidinyl and pyridinyl-pyrrolopyridinones, process for their preparation and their use as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2017-03-28 | — | — | US | disclosed |
| US-20160166575-A1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2016-06-16 | — | — | US | disclosed |
| EP-2997030-A1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2016-03-23 | — | — | EP | disclosed |
| US-20150299192-A1 | SUBSTITUTED PYRIMIDINYL AND PYRIDINYL-PYRROLOPYRIDINONES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2015-10-22 | — | — | US | disclosed |
| US-8987275-B2 | Indazole compounds and their uses | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2015-03-24 | — | — | US | disclosed |
| US-8987275-B2 | Indazole compounds and their uses | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2015-03-24 | — | — | US | disclosed |
| WO-2014184069-A1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2014-11-20 | — | — | WO | disclosed |
| US-20130184287-A1 | INDAZOLE COMPOUNDS AND THEIR USES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2013-07-18 | — | — | US | disclosed |
| US-20130184287-A1 | INDAZOLE COMPOUNDS AND THEIR USES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2013-07-18 | — | — | US | disclosed |
| EP-2547661-A2 | INDAZOLE COMPOUNDS AND THEIR USES | Dana-Farber Cancer Institute, Inc. (US) | 2013-01-23 | — | — | EP | disclosed |
| WO-2011115725-A2 | INDAZOLE COMPOUNDS AND THEIR USES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2011-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130184287-A1 | INDAZOLE COMPOUNDS AND THEIR USES | OAT, CYP3A43, CYP11B2 | KIT 1922/4885EPHA2 4170/4885BRAF 3191/4885 |
| US-20160166575-A1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | RET, DCK, PRKD2 | KIT 582/4885EPHA2 1160/4885BRAF 61/4885 |
| US-20150299192-A1 | SUBSTITUTED PYRIMIDINYL AND PYRIDINYL-PYRROLOPYRIDINONES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | RET, MAP3K8, MAP3K1 | KIT 463/4885EPHA2 902/4885BRAF 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.